Neue Forschungsergebnisse zum Kolonkarzinom, Magenkarzinom, Sarkomen und Bronchialkarzinom

 

 Buy Article Permissions and Reprints

Zusammenfassung

In der adjuvanten Chemotherapie des Kolonkarzinoms im Stadium III sollte bei Patienten bis 70 Jahre die Gabe von infusionalem Fluorouracil (5-FU) oder oralem Capecitabin in Kombination mit Oxaliplatin Standard sein. Ein neuer Standard für die palliative Therapie des Her2/neu-positiven fortgeschrittenen Magenkarzinoms und des Karzinoms des gastroösophagealen Übergangs ist die Behandlung mit Trastuzumab in Kombination mit einer Chemotherapie. Patienten mit Hochrisiko-Weichteilsarkomen profitieren neben der chirurgischen Resektion und Nachbestrahlung von einer neoadjuvanten Chemotherapie in Kombination mit regionaler Tiefenhyperthermie. Für Patienten mit Bronchialkarzinom steht nach der EGFR-Mutationsanalyse ein weiterer personalisierter Therapieansatz kurz vor der Routineanwendung: Neben dem EGFR-Mutationsstatus sollen vor allem Nie-Raucher zukünftig auch auf eine Aberration im ALK-Gen untersucht werden.

Abstract

In patients up to 70 years of age with colon carcinoma stage III adjuvant chemotherapy with infusions of fluorouracil (5-FU) or oral capecitabine combined with oxaliplatin should be the standard method. A new standard for the palliative treatment of Her2/newly positive advanced gastric cancer and cancer at the gastro-esophageal junction is the administration of trastuzumab combined with chemotherapy. Patients with high-risk soft tissue sarcoma can be helped, in addition to surgical resection and subsequent radiotherapy, by neoadjuvant chemotherapy combined with regional deep hyperthermia. For patients with lung cancer additional individualized treatment is about to become routine. In addition to the EGFR mutation status, all non-smokers should in future be tested for aberration in the anaplastic lymphoma kinase (ALK) gene.

Literatur

• 1 Albert S R, Sargent D J, Smyrk T C. et al . Adjuvant mFOLFOX with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147.  J Clin Oncol. 2010;  28 18s (suppl; abstr CRA3507)
  Google Scholar
• 2 André T, Boni C, Navarro M. et al . Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.  J Clin Oncol. 2009;  27 3109-16
  Google Scholar
• 3 Bang Y J, Van Cutsem E. et al . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.  Lancet. 2010;  376 687-697
  Google Scholar
• 4 Haller D, Taberno J, Maroun J. et al . First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study).  Eur J Cancer . 2009;  7 (Suppl. 3) 4
  Google Scholar
• 5 Issels R D, Lindner L H, Verweij J. et al . Neo-adjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-tissue sarcoma: a randomized phase 3 multicentre study.  Lancet Oncol. 2010;  11 561-570
  Google Scholar
• 6 Kang Y, Ohtsu A, Van Cutsem E. et al . AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC).  J Clin Oncol. 2010;  28 (Suppl.) 18s (Abstract LBA4007)
  Google Scholar
• 7 Kuebler J P, Wieand H S, O’Connell M J. et al . Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.  J Clin Oncol. 2007;  25 2198-204
  Google Scholar
• 8 Kwak E L, Bang Y J, Camidge D R. et al . Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.  N Engl J Med. 2010;  363 1693-703
  Google Scholar
• 9 McCleary J, Meyerhardt J, Green E. et al, The ACCENT Collaborative Group . Impact of older age on the efficacy of newer adjuvant therapies in > 12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database.  J Clin Oncol. 2009;  27 (Suppl.) 15s (Abstract 4010)
  Google Scholar
• 10 Pao W, Miller V, Zakowski M. et al . EGF receptor gene mutations are common in lung cancers from „never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib.  Proc Natl Acad Sci USA. 2004;  101 13 306
  Google Scholar
• 11 Rosell R, Moran T, Queralt B S. et al . Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.  N Engl J Med. 2009;  361 958-967
  Google Scholar
• 12 Schmiegel W, Pox C, Adler G. et al . S3-Guidelines Conference „Colorectal Carcinoma” 2004.  Z Gastroenterol. 2004;  42 1129-1177
  Google Scholar
• 13 Schmiegel W, Reinacher-Schick A, Arnold D. et al . Update S3-guideline „colorectal cancer” 2008.  Z Gastroenterol. 2008;  46 799-840
  Google Scholar
• 14 Twelves C, Wong A, Nowacki M P. et al . Capecitabine as adjuvant treatment for stage III colon cancer.  N Engl J Med. 2005;  352 2696-2704
  Google Scholar
• 15 Wendtner C M, Abdel-Rahman S, Krych M. et al . Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas.  J Clin Oncol. 2002;  20 3156-3164
  Google Scholar
• 16 Wolmark N, Yothers G, OŽConnell J M. et al . A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08.  J Clin Oncol. 2009;  27 (Suppl.) 18s; (Abstract LBA4)
  Google Scholar
• 17 Schmiegel W, Pox C, Arnold R, Porschen R, Rödel C, Reinacher-Schick A. Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases.  Dtsch Arztebl Int. 2009;  106 843-848
  Google Scholar

Prof. Dr. C.-M. Wendtner

Klinik I für Innere Medizin
Klinikum der Universität zu Köln

Kerpener Straße 62

50937 Köln

Email: Clemens.Wendtner@uni-koeln.de